Cancer in Chile

IARC estimates 59,887 new cancer cases and 31,498 cancer deaths in Chile in 2024; the commonest new cancers are prostate, colorectum and stomach. This page is assembled automatically from OnCo's data: 314 trials with a site there, 2 institutions, 3 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

59,887

all cancers

Deaths

31,498

all cancers

Incidence rate

161.9

per 100,000, age-standardised

Mortality rate

83.3

per 100,000, age-standardised

Cumulative risk

15.5%

of a cancer by age 74

Population

19,764,777

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	8,758	41.1	Prostate cancer
Colorectum	7,965	21.2	Colorectal cancer
Stomach	5,494	14.8	Gastric & gastro-oesophageal junction cancer
Breast	5,141	29.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	4,368	11.5	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Kidney	2,306	6.7	Renal cell carcinoma
Gallbladder	2,068	5.6	Gallbladder cancer
Cervix uteri	1,905	12.0	Cervical cancer
Liver and intrahepatic bile ducts	1,842	4.9	Hepatocellular carcinoma
Pancreas	1,813	4.8	Pancreatic ductal adenocarcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	3,965	10.3	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	3,794	9.9	Colorectal cancer
Stomach	3,511	9.2	Gastric & gastro-oesophageal junction cancer
Prostate	2,605	12.2	Prostate cancer
Breast	1,829	10.1	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	1,778	4.6	Pancreatic ductal adenocarcinoma
Liver and intrahepatic bile ducts	1,741	4.5	Hepatocellular carcinoma
Gallbladder	1,156	3.1	Gallbladder cancer
Kidney	1,132	3.1	Renal cell carcinoma
Leukaemia	868	2.8	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Incidence: method 3c, national mortality estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Chile”, in South America (Latin America and the Caribbean), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

314 trials in OnCo · 115 recruiting overall

314 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248	Phase 3	Recruiting	Merck Sharp & Dohme LLC	219	2026-10-07
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111	Phase 2	Recruiting	Merck Sharp & Dohme LLC	72	2026-10-07
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497	Phase 3	Recruiting	Merck Sharp & Dohme LLC	244	2026-10-07
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34 NCT06731907	Phase 2	Recruiting	Merck Sharp & Dohme LLC	41	2026-10-07
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa NCT06091865	Phase 3	Recruiting	Regeneron Pharmaceuticals	194	2026-10-07
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	58	2026-10-07
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re NCT05730036	Phase 3	Recruiting	Regeneron Pharmaceuticals	159	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827	Phase 3	Recruiting	Merck Sharp & Dohme LLC	112	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) NCT06780098	Phase 2	Recruiting	Merck Sharp & Dohme LLC	46	2026-10-07
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	50	2026-10-07
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) NCT07489495	Phase 3	Recruiting	Merck Sharp & Dohme LLC	99	2026-10-06
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	82	2026-10-06
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	43	2026-10-06
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	55	2026-10-06
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807	Phase 3	Recruiting	Merck Sharp & Dohme LLC	200	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc NCT07216703	Phase 3	Recruiting	Merck Sharp & Dohme LLC	180	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	27	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) NCT06979596	Phase 2	Recruiting	Merck Sharp & Dohme LLC	60	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	64	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Chile, captured 2026-10-07 to 2026-10-08. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Chile is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

2 institutions

Fundación Arturo López Pérez Instituto Nacional del Cáncer (Chile)

3 people

People whose main affiliation in OnCo is an institution or company in Chile.

Berta Cerda Álvarez Cristián Ayala Munita Rolando Medeiros

Screening, vaccination and law

Term

Chile's national cervical cancer screening programme

Chile runs a national cervical cancer screening programme started in 1986, offering HPV test with cytology (co-testing) and cytology (Pap test), as recorded by IARC's CanScreen5 survey (2020).

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Chile is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Chile's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Chile, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Chile's own sources, beyond the programme records above.

A deep dive for Chile is ranked 26 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/cl.json; every country: /api/v1/countries.json.